Summary
Duchenne muscular dystrophy is an xlinked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.
This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.
The report includes as follows:
The report provides current data, historical overview and future forecast.
The report includes an indepth analysis of the Global market for Duchenne Muscular Dystrophy , covering Global total and major region markets.
The data of 20172025 are included. Allinclusive market are given through data on sales, consumption, and prices Global total and by major regions.
The report provides introduction of leading Global manufacturers.
Duchenne Muscular Dystrophy market prospects to 2025 are included in sales, consumption and price.
Market Segment as follows:
By Region / Countries
North America U.S., Canada, Mexico
Europe Germany, U.K., France, Italy, Russia, Spain etc
AsiaPacific China, India, Japan, Southeast Asia etc
South America Brazil, Argentina etc
Middle East Africa Saudi Arabia, South Africa etc
By Type
Deflazacort
Prednisone
Others
By EndUser / Application
Male
Female
By Company
PTC Therapeutics
Sarepta Therapeutics
BristolMyers Squibb
ITALFARMACO
BioMarin
Daiichi Sankyo
Solid Biosciences
Summit Therapeutics
FibroGen
NS Pharma
Pfizer
ReveraGen BioPharma
Wave Life
Genethon
Santhera Pharmaceuticals